Artrya Limited · ASX:AYA
Artrya — Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum 2025
18 slides from Artrya's conference presentation, Nov 20, 2025
Slide 1: ASX announcement: Canaccord Genuity forum presentation
Coronary Artery Disease. We see you. Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PERTH, Australia, 20 November 2025: Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real
Slide 2: For more information
For more information: Corporate Enquiries Investor & Media Enquiries John Konstantopoulos David Allen or John Granger Co-Founder and Chief Executive Officer Hawkesbury Partners Tel: +61 8 6478 7816 Tel: +61 499 100 038 or +61 410 577 155 Email: contact@artrya.com Email: investors@artrya.com For person
Slide 3: 2025 Canaccord Healthcare Conference Presentation
For personal use only (ASX: AYA) 2025 Canaccord Healthcare Conference Presentation [ Advancing Commercialisation Reshaping the Future of [ Heart Care NOT FOR RELEAS E TO U.S . WIRE SERVICES OR DIS TRIBUTIO N IN THE UNITED STATES
Slide 4: Important Notice
Important Notice IMPORTANT NOTICE AND DISCLAIMER The Presentation Materials contain summary information about the Company and its activities which is current as at These presentation materials have been prepared by Artrya Limited (Artrya or Company). By receiving the the date of the Presentation Mat
Slide 5: Artrya at a Glance – an attractive market and model
Artrya at a Glance – an attractive market and model Salix® is the only real-time, point of care platform globally delivering end-to-end CCTA assessment For personal use only Attractive Market Commercial Momentum Differentiated Product • (ASX: AYA) - ~AU$550m market cap • Unified CCTA Reporting Platf
Slide 6: What's broken in coronary diagnosis today
What’s broken in coronary diagnosis today A diagnosis workflow that is slow, burdensome for clinicians, and built for another era For personal use only CAD is deadly Plaque goes Long wait times and Unnecessary and common unseen high uncertainty procedures The Impact • Delays in diagnosis 1 in 3 55%
Slide 7: Significant Cardiac CT Growth
Significant Cardiac CT Growth Hospitals are under pressure to reduce costs, improve patient care and only have finite resources For personal use only Drivers of CCTA Growth Pressures on Hospitals Artrya’s Solution - Salix® • Guidelines: CCTA is now first- • CCTA demand is outpacing line for chest pa
Slide 8: Salix provides streamlined, real-time patient assessment
Salix® provides streamlined, real-time patient assessment Clear clinical insights into actionable decisions in minutes For personal use only Point of care real-time analysis – without humans CCTA analysis in under 10 mins increases capacity and throughput Real-time Plaque and Flow Analysis Automated
Slide 9: From off-site workflows to point of care 10-minute decision
From off-site workflows to point of care 10-minute decision Salix fits directly into the existing clinical workflow with human intervention ® For personal use only Onsite - Manual Assessment Workstation Review & CCTA Report Currently vendors Prepare Clinician Current Finalizes Report • Inefficient a
Slide 10: Salix provides a point of care, CCTA reporting platform
Salix® provides a point of care, CCTA reporting platform Real-time CCTA, Plaque, and Flow1 analysis from a single platform within 10 minutes For personal use only Benefits: Clinician-Controlled, High-Efficiency 1 Analysis Faster triage, standardized reports, 2 streamlined workflow Real-time Plaque a
Slide 11: Strong value proposition for all stakeholders
Strong value proposition for all stakeholders Salix® transforms accuracy, efficiency, and patient outcomes across the healthcare ecosystem. For personal use only Patients Clinicians Health Systems Faster results and improved outcomes Integrated workflow speeds reporting and Drive efficiency, increas
Slide 12: Salix platform roadmap: today, next & future
Salix® platform roadmap: today, next & future Real-time modules run on the same Salix® platform, enabling scalable expansion across customers For personal use only Today (Live) Next (FDA Review) Future (Expansion) Real-time CCTA platform with Growth from blood flow Product expansion to unlock plaque
Slide 13: U.S. Market Focus
For personal use only U.S. Market Focus Commercial pathway for 2026 and beyond
Slide 14: Traction to date
Traction to date Active in the U.S. market with commercial, clinical, regulatory and capital momentum. For personal use only Foundation Customers Strong FDA Progress SAPPHIRE Study Revenue Growth • Tanner Health live • Salix® platform and • Multi-site U.S. • Strong pipeline plaque module FDA- SAPPHI
Slide 15: SAPPHIRE Study: Clinical Overview
SAPPHIRE Study: Clinical Overview Validate the novel Salix® Plaque Dispersion Score (PDS) to risk-stratify patients based on individual plaques and improve treatment decisions. For personal use only Overview Study Phases To evaluate Salix® PDS as a non-invasive tool for assessing cardiovascular risk
Slide 16: Our U.S. footprint across leading health systems
Our U.S. footprint across leading health systems Foundation customers, SAPPHIRE sites, and our Atlanta support pod working together to drive U.S. growth. For personal use only Mass. General Massachusetts 12 hospitals 32 Cardiology Centres Cone Health North Carolina 5 hospitals 24 Heart Centres Ascen
Slide 17: Outlook: Scaling Salix in the U.S.
Outlook: Scaling Salix® in the U.S. Building commercial momentum, strengthening clinical evidence, and extending product leadership For personal use only Drive Commercial Growth • Accelerate U.S. rollout • Near term adoption for Platform and Plaque • Salix®️ expanding across hospital systems Clinica
Slide 18: For personal use only
For personal use only www.artrya.com John Konstantopoulos Co-Founder and Chief Executive Officer +61 8 6478 7816 contact@artrya.com
Artrya — Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum 2025 on 6ix